selinexor + dexamethasone + pomalidomide + elotuzumab

This is a combination regimen of four drugs used in clinical trials for multiple myeloma and plasma cell neoplasms: - **Selinexor** is a selective inhibitor of nuclear export (SINE) that blocks Exportin 1 (XPO1), leading to retention and activation of tumor suppressor proteins within the nucleus[5]. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects, contributing broad cytotoxic activity against some hematologic malignancies[5]. - **Pomalidomide** is an immunomodulatory imide drug (IMiD) that blocks the growth of cancer cells and modulates immune function[5]. - **Elotuzumab** is a monoclonal antibody targeting SLAMF7 on myeloma and immune cells, enhancing immune-mediated myeloma cell killing[5]. This four-drug regimen is under investigation for relapsed/refractory multiple myeloma (RRMM) and related plasma cell disorders, especially after failure of prior proteasome inhibitor, IMiD, and anti-CD38 antibody therapies[9][5]. The combination is under evaluation for efficacy, safety, and impact on quality of life in phase 3 trials[3][9]. The combination regimen is typically administered in 28-day cycles: selinexor and dexamethasone orally once weekly, pomalidomide orally daily for 21 days (with a 7-day break), and elotuzumab intravenously on specific days[7][5].

Brand names

no unique combination brand name is established for all four; individual brand names include XPOVIO (selinexor), Decadron (dexamethasone; regionally), Pomalyst (pomalidomide), Empliciti (elotuzumab)

Other names

SPd + elotuzumabselinexor + pomalidomide + dexamethasone + elotuzumab